ArticleJournal of family medicine and primary care2026
Global, regional, and national burden of high body mass index-related type 2 diabetes from 1990 to 2021 and projections for 2040.
Article in Journal of family medicine and primary care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Wheat Bioactive Compounds and Human Health: A Review of Nutraceutical Potential, Molecular Mechanisms and AI-Assisted Functional Food Innovation.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To analyze the global, regional, and national burden of high body mass index (BMI)-related type 2 diabetes from 1990 to 2021 and projections for 2040. Methods: The death and disability-adjusted life years (DALYs) with the corresponding age-standardized rates of high BMI-related type 2 diabetes were analyzed using the Global Burden of Disease 2021. The death and DALYs for 2040 were forecasted with an autoregressive integrated moving average model. Results: Globally, 723,719 (95% uncertainty interval [UI]: 306,923 to 1,075,367) death cases and 39,309,214 (95% UI: 19,146,834 to 56,417,300) DALYs cases were recorded in 2021. The age-standardized death rate was 8.46 (3.55 to 12.62) per 100,000 population, and the DALYs rate was 452.55 (220.36 to 650.49) per 100,000 population. Compared with those in 1990, the death and DALYs rates increased by 33.75% and 79.92%, respectively. In 2021, Oceania, especially Fiji, had the highest age-standardized death and DALYs rates. The global burden on males was similar to that on females. The age-standardized death rate peaked in the 65-69 age group and DALYs rate in age 60-64 years. Low-middle sociodemographic index regions showed the highest age-standardized death and DALYs rates. By 2040, age-standardized death and DALYs rates were projected to increase by 14.7% and 35.43%, respectively. Conclusion: Global burden is heavy, significant regional, and national disparities remained, which emphasizes the need for targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.